To see the other types of publications on this topic, follow the link: Control; Infection; Immunization.
Journal articles on the topic 'Control; Infection; Immunization'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 50 journal articles for your research on the topic 'Control; Infection; Immunization.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.
1
Nazarko, Linda. "Infection control: immunization update." Nursing and Residential Care 10, no. 2 (February 2008): 74–77. http://dx.doi.org/10.12968/nrec.2008.10.2.28123.
Full text
2
Valenti, William M. "Infection Control and Employee Health: Rubella Prevention Programs." Infection Control 6, no. 8 (August 1985): 329–32. http://dx.doi.org/10.1017/s0195941700063219.
Full textAbstract:
In recent years, increased emphasis has been placed on immunization of adults. The reintroduction of the pneumococcal vaccine in 1976 seems to have begun a new era in adult medicine that targets certain vaccines toward adults. Prior to this, most of our efforts at immunization in the US were directed toward young children. Although the pneumococcal vaccine has been underutilized, publications from the CDC and the American College of Physicians suggest that this particular public health strategy will be with us for some time to come.
3
Delpino, M. Victoria, Silvia M. Estein, Carlos A. Fossati, and Pablo C. Baldi. "Partial Protection against Brucella Infection in Mice by Immunization with Nonpathogenic Alphaproteobacteria." Clinical and Vaccine Immunology 14, no. 10 (August 22, 2007): 1296–301. http://dx.doi.org/10.1128/cvi.00459-06.
Full textAbstract:
ABSTRACT Previous findings indicate that Brucella antigens and those from nonpathogenic alphaproteobacteria (NPAP) are cross-recognized by the immune system. We hypothesized that immunization with NPAP would protect mice from Brucella infection. Mice were immunized subcutaneously with heat-killed Ochrobactrum anthropi, Sinorhizobium meliloti, Mesorhizobium loti, Agrobacterium tumefaciens, or Brucella melitensis H38 (standard positive control) before intravenous challenge with Brucella abortus 2308. Cross-reacting serum antibodies against Brucella antigens were detected at the moment of challenge in all NPAP-immunized mice. Thirty days after B. abortus challenge, splenic CFU counts were significantly lower in mice immunized with O. anthropi, M. loti, and B. melitensis H38 than in the phosphate-buffered saline controls (protection levels were 0.80, 0.66, and 1.99 log units, respectively). In mice immunized intraperitoneally with cytosoluble extracts from NPAP or Brucella abortus, protection levels were 1.58 for the latter, 0.63 for O. anthropi, and 0.40 for M. loti. To test whether the use of live NPAP would increase protection further, mice were both immunized and challenged by the oral route. Immunization with NPAP induced a significant increase in serum immunoglobulin G (IgG), but not serum or fecal IgA, against Brucella antigens. After challenge, anti-Brucella IgA increased significantly in the sera and feces of mice orally immunized with O. anthropi. For all NPAP, protection levels were higher than those obtained with systemic immunizations but were lower than those obtained by oral immunization with heat-killed B. abortus. These results show that immunization with NPAP, especially O. anthropi, confers partial protection against Brucella challenge. However, such protection is lower than that conferred by immunization with whole Brucella or its cytosoluble fraction.
4
Smith, Philip W., and Patricia G. Rusnak. "Infection Prevention and Control in the Long-Term-Care Facility." Infection Control & Hospital Epidemiology 18, no. 12 (December 1997): 831–49. http://dx.doi.org/10.1017/s0195941700086562.
Full textAbstract:
AbstractMore than 1.5 million residents reside in US nursing homes. In recent years, the acuity of illness of nursing home residents has increased. Long-term-care facility residents have a risk of developing nosocomial infection that is similar to acute-care hospital patients. A great deal of information has been published concerning infections in the long-term-care facility, and infection control programs are nearly universal.This position paper reviews the literature on infections and infection control programs in the long-term-care facility, covering such topics as tuberculosis, bloodborne pathogens, epidemics, isolation systems, immunization, and antibiotic-resistant bacteria. Recommendations are developed for long-term-care infection control programs based on interpretation of currently available evidence. The recommendations cover the structure and function of the infection control program, including surveillance, isolation, outbreak control, resident care, and employee health. Infection control resources also are presented.
5
Cox, F. E. G. "Interactions between chemotherapy and immunity in bovine theileriosis." Parasitology 105, S1 (January 1992): S79—S84. http://dx.doi.org/10.1017/s0031182000075387.
Full textAbstract:
SUMMARYIn bovine theileriosis the use of chemotherapy to control an infection sufficiently long to permit the establishment of a solid protective immune response has been developed as a routine vaccination procedure. Infections withTheileria parvaandT. annulatacan be prevented by the administration of carefully controlled numbers of sporozoites simultaneously with a long acting tetracycline and this form of immunization has been widely used for the control of East Coast fever in Africa with considerable success. In this review, the nature of the chemotherapy, the immune response and the interactions between chemotherapy and immunity in the development of infection-and-treatment immunization procedures are discussed.
6
Li, Zhong-Yuan, Jing Lu, Nian-Zhang Zhang, Hany M. Elsheikha, Jun-Ling Hou, Hai-Ting Guo, and Xing-Quan Zhu. "Immunization with plasmid DNA expressing Heat Shock Protein 40 confers prophylactic protection against chronic Toxoplasma gondii infection in Kunming mice." Parasite 25 (2018): 37. http://dx.doi.org/10.1051/parasite/2018040.
Full textAbstract:
Toxoplasma gondii causes one of the most common protozoal diseases of humans and animals worldwide. With the aim of designing an effective vaccine against T. gondii infection, we examined the immunogenicity of a DNA vaccine expressing heat shock protein 40 (HSP40) against challenge with T. gondii (type I RH and type II Pru) strains in Kunming mice. The plasmid pVAX1-HSP40 was constructed and used to immunize mice by intramuscular injection for three sequential immunizations with two-week intervals. This immunization regimen significantly reduced parasite cyst burden in pVAX1-HSP40-immunized mice (1871.9 ± 142.3) compared with control mouse groups immunized with pVAX1 (3479.2 ± 204.4), phosphate buffered saline (3024.4 ± 212.8), or left untreated (3275.0 ± 179.8) as healthy controls (p < 0.01). However, immunization failed to protect mice against challenge with the virulent RH strain. There was a significant increase in T lymphocyte subclasses (CD3e+CD4+ T and CD3e+CD8a+ T lymphocytes) in splenic tissues in immunized mice compared with controls (p < 0.05). However, the level of antibodies, lymphocyte proliferation and concentration of cytokines (IFN-γ, IL-2, IL-4, IL-10 and IL-12p70) were not significantly different between immunized and control mouse groups (p < 0.05). These data indicate that pVAX1-HSP40 induced specific immune responses and achieved a significant reduction in the number of brain cysts in Pru-infected mice, and thus can be tested in future immunization studies along with plasmids containing other immunogenic proteins as a cocktail vaccine to fully abolish chronic toxoplasmosis.
7
Anand, Puneet, Rakhi Jain, and Gunjan Gunjan. "A cross sectional study on infection control practices among mothers attending immunization clinic at a teaching hospital in Haryana." Asian Pacific Journal of Health Sciences 4, no. 1 (March 30, 2017): 107–11. http://dx.doi.org/10.21276/apjhs.2017.4.1.19.
Full text
8
Sukarjati, Sukarjati, Susie Amilah, and Sudjarwo Sudjarwo. "Toxicity of 32.2 kDa MW Escherichia coli Pili Adhesin Isolated from Infertile Male Semen in Reproductive System." Folia Medica Indonesiana 54, no. 2 (July 5, 2018): 146. http://dx.doi.org/10.20473/fmi.v54i2.8866.
Full textAbstract:
Escherichia coli (E. coli) is the leading cause of male genital tract infection with no symptoms of infertility. Protein E. coli pili hemagglutinin isolated from infertile male sperm with 32.2 kDa MW acts as adhesion in spermatozoa. This study aimed to prove whether E. coli pili adhesin 32.2 kDa MW is toxic to male reproductive system. Samples consisted of spermatozoa of 30 guinea pigs divided into three groups: control, immunized with E. coli pili adhesin 32.2 kDa MW protein, and transurethral infected E. coli. Observations of sperm motility, vitality and morphology were performed under a microscope. MDA levels and sperm DNA damage were measured by a spectrophotometer and comet assay method and observed using a fluorescent microscope. There was no difference between control and immunization group of E. coli pili adhesin in motility (p=0.499), vitality (p=0.817) and morphology (p=0.176); between control and transuretral infection groups in motility (p=0.000), vitality (p=0.000) and morphology (p=0.000); and between control and both treatment groups in motility (p=0.001), vitality (p=0,000) and morphology (p=0.000). Histologic analysis showed E. coli pili adhesin of 32.2 kDa MW immunization group did not suffer from testicular tissue damage, while the positive group showed a deterioration of seminiferous tubular cells. MDA levels differed between immunization group E. coli pili, transurethral infection group, and control (p=0.024) and between transurethral and control (p=0.007) groups. However, between control and immunized group with E. coli pili protein showed no difference (p=0.251). DNA damage differed (p=0.000) between immunized group with E. coli pili, transurethral infection and control group; between control and transurethral infected group (p=0.000); and between transurethral infection group and E. coli pili protein immunization group (p=0.000). However, between control and E. coli pili immunization group showed no difference (p=0.600). In conclusion, E. coli pili adhesin 32.2 kDa MW protein is not toxic for sperm quality and the quality of sperm molecules.
9
Clarke, Stuart C. "Control of pneumococcal disease in the United Kingdom – the start of a new era." Journal of Medical Microbiology 55, no. 8 (August 1, 2006): 975–80. http://dx.doi.org/10.1099/jmm.0.46579-0.
Full textAbstract:
In 2000, a multi-valent pneumococcal conjugate vaccine, known as Prevnar, was licensed for use in infants and young children in the USA. The subsequent introduction of the vaccine into the childhood immunization schedule in that country led to a significant decrease in pneumococcal disease. The vaccine is effective against invasive and non-invasive pneumococcal infection, can be used in young children as well as adults and, like all conjugate vaccines, provides long-lasting immunity. Moreover, it reduces the incidence of antibiotic resistance because a number of resistant serotypes are targeted by the vaccine. Prevnar, also known as Prevenar, has since been licensed in numerous countries, including the UK. On 8 February 2006, the Departments of Health in England, Scotland and Wales announced the inclusion of Prevenar in the childhood immunization schedule. This announcement has important implications for pneumococcal infection, disease surveillance and immunization policy in the UK.
10
Kesavalu, Lakshmyya, Stanley C. Holt, and Jeffrey L. Ebersole. "Lack of Humoral Immune Protection againstTreponema denticola Virulence in a Murine Model." Infection and Immunity 67, no. 11 (November 1, 1999): 5736–46. http://dx.doi.org/10.1128/iai.67.11.5736-5746.1999.
Full textAbstract:
ABSTRACT This study investigated the characteristics of humoral immune responses to Treponema denticola following primary infection, reinfection, and active immunization, as well as immune protection in mice. Primary infection with T. denticolainduced a significant (400-fold) serum immunoglobulin G (IgG) response compared to that in control uninfected mice. The IgG response to reinfection was 20,000-fold higher than that for control mice and 10-fold higher than that for primary infection. Mice actively immunized with formalin-killed treponemes developed serum antibody levels seven- to eightfold greater than those in animals after primary infection. Nevertheless, mice with this acquired antibody following primary infection or active immunization demonstrated no significant alterations of lesion induction or decreased size of the abscesses following a challenge infection. Mice with primary infection developed increased levels of IgG3, IgG2b, and IgG2a antibodies, with IgG1 being lower than the other subclasses. Reinfected mice developed enhanced IgG2b, IgG2a, and IgG3 and less IgG1. In contrast, immunized mice developed higher IgG1 and lower IgG3 antibody responses to infection. These IgG subclass distributions indicate a stimulation of both Th1 and Th2 activities in development of the humoral immune response to infection and immunization. Our findings also demonstrated a broad antigen reactivity of the serum antibody, which was significantly increased with reinfection and active immunization. Furthermore, serum antibody was effective in vitro in immobilizing and clumping the bacteria but did not inhibit growth or passively prevent the treponemal infection. These observations suggest that humoral immune responses, as manifested by antibody levels, isotype, and antigenic specificity, were not capable of resolving a T. denticola infection.
11
Gully, Paul R. "Control of Sexually Transmitted Disease: The Canadian Perspective." Canadian Journal of Infectious Diseases 2, suppl a (1991): 9–12. http://dx.doi.org/10.1155/1991/473236.
Full textAbstract:
The ability to control a disease depends on knowledge of its epidemiology. Such information on sexually transmitted diseases (STDs) can be ascertained by surveillance data involving the analysis of notification reports, as well as laboratory reports, hospital discharge data, and data from sentinel clinics and health units. In the case of sexually transmitted hepatitis B, notification data will probably have to be corroborated by data from sentinel clinics, health units or physicians. A vigorous attempt must be made to elucidate the mode of transmission in acute cases and newly discovered carriers. Appropriate treatment, contact tracing and primary prevention strategies appear to have had some success in controlling gonorrhea and syphilis. Rates of genital chlamydial infection may also be reduced by the same methods. These diseases will, however, persist in certain 'core groups'. Control of sexually transmitted hepatitis B will require a primary prevention strategy of risk reduction, sexual health promotion and immunization. Targeted immunization programs on their own are not Likely to work. Thus, universal immunization will probably be required along with public acceptance of immunization against STDs and appropriate human and financial resources. Reliable surveillance data will be required for program evaluation.
12
Shillova, Nita, Savannah E. Howe, Besmir Hyseni, Deahneece Ridgell, Derek J. Fisher, and Vjollca Konjufca. "Chlamydia-Specific IgA Secretion in the Female Reproductive Tract Induced via Per-Oral Immunization Confers Protection against Primary Chlamydia Challenge." Infection and Immunity 89, no. 1 (November 2, 2020): e00413-20. http://dx.doi.org/10.1128/iai.00413-20.
Full textAbstract:
ABSTRACTChlamydia trachomatis is an obligate intracellular pathogen that causes sexually transmitted disease. In women, chlamydial infections may cause pelvic inflammatory disease (PID), ectopic pregnancy, and infertility. The role of antibodies in protection against a primary Chlamydia infection is unclear and was a focus of this work. Using the C. muridarum mouse infection model, we show that intestinal mucosa is infected via intranasal (i.n.) or per-oral (p.o.) Chlamydia inoculation and that unlike the female reproductive tract (FRT) mucosa, it halts systemic Chlamydia dissemination. Moreover, p.o. immunization or infection with Chlamydia confers protection against per-vaginal (p.v.) challenge, resulting in significantly decreased bacterial burden in the FRT, accelerated Chlamydia clearance, and reduced hydrosalpinx pathology. In contrast, subcutaneous (s.c.) immunization conferred no protection against the p.v. challenge. Both p.o. and s.c. immunizations induced Chlamydia-specific serum IgA. However, IgA was found only in the vaginal washes and fecal extracts of p.o.-immunized animals. Following a p.v. challenge, unimmunized control and s.c.-s.c.-immunized animals developed Chlamydia-specific intestinal IgA yet failed to develop IgA in the FRT, indicating that IgA response in the FRT relies on the FRT to gastrointestinal tract (GIT) antigen transport. Vaginal secretions of p.o.-immunized animals neutralize Chlamydia in vivo, resulting in significantly lower Chlamydia burden in the FRT and Chlamydia transport to the GIT. We also show that infection of the GIT is not necessary for induction of protective immunity in the FRT, a finding that is important for the development of p.o. subunit vaccines to target Chlamydia and possibly other sexually transmitted pathogens.
13
Pueschel, Karen, Annette Tietz, Mary Carsillo, Michael Steward, and Stefan Niewiesk. "Measles Virus-Specific CD4 T-Cell Activity Does Not Correlate with Protection against Lung Infection or Viral Clearance." Journal of Virology 81, no. 16 (June 6, 2007): 8571–78. http://dx.doi.org/10.1128/jvi.00160-07.
Full textAbstract:
ABSTRACT Acute measles in children can be prevented by immunization with the live attenuated measles vaccine virus. Although immunization is able to induce CD4 and CD8 T cells as well as neutralizing antibodies, only the latter have been correlated with protective immunity. CD8 T cells, however, have been documented to be important in viral clearance in the respiratory tract, whereas CD4 T cells have been shown to be protective in a mouse encephalitis model. In order to investigate the CD4 T-cell response in infection of the respiratory tract, we have defined a T-cell epitope in the hemagglutinin (H) protein for immunization and developed a monoclonal antibody for depletion of CD4 T cells in the cotton rat model. Although the kinetics of CD4 T-cell development correlated with clearance of virus, the depletion of CD4 T cells during the primary infection did not influence viral titers in lung tissue. Immunization with the H epitope induced a CD4 T-cell response but did not protect against infection. Immunization in the presence of maternal antibodies resulted in the development of a CD4 T-cell response which (in the absence of neutralizing antibodies) did not protect against infection. In summary, CD4 T cells do not seem to protect against infection after immunization and do not participate in clearance of virus infection from lung tissue during measles virus infection. We speculate that the major role of CD4 T cells is to control and clear virus infection from other affected organs like the brain.
14
Pascale, Juan M., Margaret M. Shaw, Pamela J. Durant, Aytza A. Amador, Marilyn S. Bartlett, James W. Smith, Richard L. Gregory, and Gerald L. McLaughlin. "Intranasal Immunization Confers Protection against Murine Pneumocystis carinii Lung Infection." Infection and Immunity 67, no. 2 (February 1, 1999): 805–9. http://dx.doi.org/10.1128/iai.67.2.805-809.1999.
Full textAbstract:
ABSTRACT To evaluate the feasibility of mucosal immunization againstPneumocystis carinii (Pc) experimental infection, female BALB/c mice were intranasally immunized three times with soluble Pc antigens plus cholera toxin fraction B (Pc-CTB); control groups received either Pc antigen, CTB, or phosphate-buffered saline (PBS) alone. Two weeks after the last immunization, five animals from each group were sacrificed, and cellular and humoral immune responses were evaluated. The remaining five mice were CD4 depleted using a monoclonal antibody against mouse CD4 and inoculated with viable Pc. Significantly higher specific lymphoproliferative responses from tracheobronchial lymph node cells, immunoglobulin M (IgM) and IgG antibody levels in serum, and bronchoalveolar lavage (BAL)-derived IgA antibody concentrations were observed in the Pc-CTB group of mice relative to control groups (P < 0.01). Five weeks after challenge, no Pc organisms were observed in the lung smears of the Pc-CTB group, while the animals receiving antigen, adjuvant, or PBS had progressively higher numbers of Pc microorganisms. By Western blot analysis, a strongly reactive 55- to 60-kDa antigen was recognized by BAL IgA and by serum IgG. In summary, mucosal immunization elicited specific cellular and humoral immune responses and protected against Pc lung infection after immunosuppression.
15
Nisa, Annisa, Ulfa Hamdanah, and Anita Dwi Ariyani. "Correlation between BCG Immunization Status and The Incidence of Tuberculosis among Children." Babali Nursing Research 1, no. 1 (March 14, 2020): 39–46. http://dx.doi.org/10.37363/bnr.2020.116.
Full textAbstract:
Introduction: A children tend to have a high risk on the tuberculosis (TB) infection. BCG immunization is well known as effective way to protect the children from the infection of TB bacteria. Therefore, the study aim was to investigate a correlation between BCG immunization status and the incidence of tuberculosis among children.
Methods: A retrospective case-control study design was used. In total 34 children, whose aged between 1 to 12 years old and visited Wonorejo Primary Health Center between September, 12nd to 16th 2019 recruited as study participant. The Chi-square test was used in this study.
Results: There was a significant correlation between BCG immunization status and the incidence of tuberculosis among children with P value = .008, < .05.
Conclusion: Among five from six children who did not received the BCG immunization were suffered with TB bacteria infection.
16
Cekinović, Đurđica, Mijo Golemac, Ester Pernjak Pugel, Jelena Tomac, Luka Čičin-Šain, Irena Slavuljica, Russell Bradford, et al. "Passive Immunization Reduces Murine Cytomegalovirus-Induced Brain Pathology in Newborn Mice." Journal of Virology 82, no. 24 (October 8, 2008): 12172–80. http://dx.doi.org/10.1128/jvi.01214-08.
Full textAbstract:
ABSTRACT Human cytomegalovirus (HCMV) is the most frequent cause of congenital viral infections in humans and frequently leads to long-term central nervous system (CNS) abnormalities that include learning disabilities, microcephaly, and hearing loss. The pathogenesis of the CNS infection has not been fully elucidated and may arise as a result of direct damage of CMV-infected neurons or indirectly secondary to inflammatory response to infection. We used a recently established model of mouse CMV (MCMV) infection in newborn mice to analyze the contribution of humoral immunity to virus clearance from the brain. In brains of MCMV-infected newborn mice treated with immune serum, the titer of infectious virus was reduced below detection limit, whereas in the brains of mice receiving control (nonimmune) serum significant amounts of virus were recovered. Moreover, histopathological and immunohistological analyses revealed significantly less CNS inflammation in mice treated with immune serum. Treatment with MCMV-specific monoclonal antibodies also resulted in the reduction of virus titer in the brain. Recipients of control serum or irrelevant antibodies had more viral foci, marked mononuclear cell infiltrates, and prominent glial nodules in their brains than mice treated with immune serum or MCMV-specific antibodies. In conclusion, our data indicate that virus-specific antibodies have a protective role in the development of CNS pathology in MCMV-infected newborn mice, suggesting that antiviral antibodies may be an important component of protective immunological responses during CMV infection of the developing CNS.
17
Rollier, C., E. Depla, J. A. R. Drexhage, E. J. Verschoor, B. E. Verstrepen, A. Fatmi, C. Brinster, et al. "Control of Heterologous Hepatitis C Virus Infection in Chimpanzees Is Associated with the Quality of Vaccine-Induced Peripheral T-Helper Immune Response." Journal of Virology 78, no. 1 (January 1, 2004): 187–96. http://dx.doi.org/10.1128/jvi.78.1.187-196.2004.
Full textAbstract:
ABSTRACT Prophylactic hepatitis C virus (HCV) vaccine trials with human volunteers are pending. There is an important need for immunological end points which correlate with vaccine efficacy and which do not involve invasive procedures, such as liver biopsies. By using a multicomponent DNA priming-protein boosting vaccine strategy, naïve chimpanzees were immunized against HCV structural proteins (core, E1, and E2) as well as a nonstructural (NS3) protein. Following immunization, exposure to the heterologous HCV 1b J4 subtype resulted in a peak of plasma viremia which was lower in both immunized animals. Compared to the naïve infection control and nine additional historical controls which became chronic, vaccinee 2 (Vac2) rapidly resolved the infection, while the other (Vac1) clearly controlled HCV infection. Immunization induced antibodies, peptide-specific gamma interferon (IFN-γ), protein-specific lymphoproliferative responses, IFN-γ, interleukin-2 (IL-2), and IL-4 T-helper responses in both vaccinees. However, the specificities were markedly different: Vac2 developed responses which were lower in magnitude than those of Vac1 but which were biased towards Th1-type cytokine responses for E1 and NS3. This proof-of-principle study in chimpanzees revealed that immunization with a combination of nonstructural and structural antigens elicited T-cell responses associated with an alteration of the course of infection. Our findings provide data to support the concept that the quality of the response to conserved epitopes and the specific nature of the peripheral T-helper immune response are likely pivotal factors influencing the control and clearance of HCV infection.
18
Martínez-Rodrigo, Abel, Daniel S. Dias, Patrícia A. F. Ribeiro, Bruno M. Roatt, Alicia Mas, Javier Carrión, Eduardo A. F. Coelho, and Gustavo Domínguez-Bernal. "Immunization with the HisAK70 DNA Vaccine Induces Resistance against Leishmania Amazonensis Infection in BALB/c Mice." Vaccines 7, no. 4 (November 14, 2019): 183. http://dx.doi.org/10.3390/vaccines7040183.
Full textAbstract:
Leishmania amazonensis is the aetiological agent of a broad spectrum of leishmaniosis in South America. It can cause not only numerous cases of cutaneous leishmaniosis but also diffuse cutaneous leishmaniosis. Considering the diversity of parasite species causing different forms of the disease that coexist in the same region, it is desirable to develop a vaccine capable of eliciting cross-protection. We have previously described the use of HisAK70 DNA vaccine for immunization of mice to assess the induction of a resistant phenotype against Leishmania major and infantum infections. In this study, we extended its application in the murine model of infection by using L. amazonensis promastigotes. Our data revealed that 14 weeks post-infection, HisAK70-vaccinated mice showed key biomarkers of protection, such as higher iNOS/arginase activity, IFN-γ/IL-10, IFN-γ/IL-4, and GM-CSF/IL-10 ratios, in addition to an IgG2a-type response when compared to the control group. These findings correlated with the presentation of lower footpad swelling and parasite burdens in the immunized compared to the control mice. Overall, this study suggests that immunization with HisAK70 may be considered a suitable tool to combat leishmaniosis as it is able to induce a potent cellular immune response, which allows to control the infection caused by L. amazonensis.
19
Moreau, Danusia, Jonathan Besney, Angela Jacobs, Dan Woods, Mark Joffe, and Rabia Ahmed. "Varicella zoster virus transmission in youth during incarceration." International Journal of Prisoner Health 12, no. 2 (June 13, 2016): 106–14. http://dx.doi.org/10.1108/ijph-11-2015-0038.
Full textAbstract:
Purpose – Facility-based Varicella zoster virus (VZV) transmission is reported in a Canadian youth offender correctional centre (YOCC). Transmission occurred from an immunocompetent youth offender (YO) with localized Herpes zoster to another immunocompetent single dose vaccinated YO, resulting in Varicella zoster (VZ) breakthrough disease. The purpose of this paper is to identify infection prevention and control (IPAC) measures utilized in this setting. Design/methodology/approach – A retrospective chart and immunization record review was conducted for two VZV cases and 27 exposed YO contacts in order to obtain demographic, clinical and immunization data. Descriptive data analysis was performed. Findings – All VZV cases and exposed contacts were male with an average age of 14.2 and 15.6 years for cases and contacts, respectively. Both cases shared the same living unit in the YOCC. There were 28 identified YO contacts, of whom 70 percent were single dose vaccinated with univalent vaccine, followed by 22 percent with a previous history of Varicella disease. All cases and contacts were born in Canada. No foreign-born populations were involved with this event. Infection control measures included additional precaution management, enhanced surveillance and environmental cleaning. As such, no hospitalizations or post-exposure immunizations were required. Originality/value – This report highlights the role that VZ breakthrough disease could play in fueling an outbreak in a high-risk environment without rapid recognition and implementation of preventative measures. It also underscores the importance of IPAC presence and public health immunization programs within correctional centers to avoid infectious disease threats.
20
Schaffer, Adam C., Robert M. Solinga, Jordan Cocchiaro, Marta Portoles, Kevin B. Kiser, Allison Risley, Suzanne M. Randall, et al. "Immunization with Staphylococcus aureus Clumping Factor B, a Major Determinant in Nasal Carriage, Reduces Nasal Colonization in a Murine Model." Infection and Immunity 74, no. 4 (April 2006): 2145–53. http://dx.doi.org/10.1128/iai.74.4.2145-2153.2006.
Full textAbstract:
ABSTRACT Staphylococcus aureus is responsible for a wide range of infections, including soft tissue infections and potentially fatal bacteremias. The primary niche for S. aureus in humans is the nares, and nasal carriage is a documented risk factor for staphylococcal infection. Previous studies with rodent models of nasal colonization have implicated capsule and teichoic acid as staphylococcal surface factors that promote colonization. In this study, a mouse model of nasal colonization was utilized to demonstrate that S. aureus mutants that lack clumping factor A, collagen binding protein, fibronectin binding proteins A and B, polysaccharide intercellular adhesin, or the accessory gene regulator colonized as well as wild-type strains colonized. In contrast, mutants deficient in sortase A or clumping factor B (ClfB) showed reduced nasal colonization. Mice immunized intranasally with killed S. aureus cells showed reduced nasal colonization compared with control animals. Likewise, mice that were immunized systemically or intranasally with a recombinant vaccine composed of domain A of ClfB exhibited lower levels of colonization than control animals exhibited. A ClfB monoclonal antibody (MAb) inhibited S. aureus binding to mouse cytokeratin 10. Passive immunization of mice with this MAb resulted in reduced nasal colonization compared with the colonization observed after immunization with an isotype-matched control antibody. The mouse immunization studies demonstrate that ClfB is an attractive component for inclusion in a vaccine to reduce S. aureus nasal colonization in humans, which in turn may diminish the risk of staphylococcal infection. As targets for vaccine development and antimicrobial intervention are assessed, rodent nasal colonization models may be invaluable.
21
Vivancos-Gallego, MJ, Alfonso Muriel, Sergio Serrano-Villar, Ana Moreno-Zamora, MJ Pérez-Elías, Carmen Quereda, JL Casado, et al. "Pneumococcal vaccination in adult people living with HIV on suppressive antiretroviral therapy: a case–control study." International Journal of STD & AIDS 31, no. 2 (December 22, 2019): 174–82. http://dx.doi.org/10.1177/0956462419882128.
Full textAbstract:
There is little information on the effectiveness of the pneumococcal vaccines (PVs), especially for the pneumococcal conjugate vaccines (PCVs), in HIV-infected patients in the modern antiretroviral era. This is a case–control study where cases were people living with HIV (PLWH) with confirmed pneumococcal infection (CPI) and controls were PLWH without CPI matched with cases by gender and year of HIV diagnosis. The selection process was blinded to the study factor (vaccination). Sample size estimation yielded 61 cases and 183 controls. We analyzed the effect of PV on CPI using Cox proportional-hazards regression model with time-dependent covariates. We included 256 subjects: 64 cases, and 192 controls. PVs had been administered to 115 (45%) patients. Only the modified Charlson Comorbidity Index (HR 1.16, 95%CI 1.06–1.27, P = 0.001) and the CD4 nadir (HR 0.99, 95% CI 0.98–0.99, P = 0.001) were independently associated with CPI. Receipt of PV was not associated with CPI after adjusting in the multivariate model with time protection as a dependent covariate (HR 0.65, 95% CI 0.35–1.32 P = 0.250). We also investigated the influence of different immunization schedules. In an adjusted model, we found no evidence of protection against CPI, including double immunization schedules (HR 0.42 95%CI 0.15–1.19 P = 0.102). In this case–control study, we could not show an association between pneumococcal vaccination and confirmed pneumococcal infection, although a protective effect of particular schedules of immunization cannot be ruled out.
22
Akaeva, Tatiana, Karen Mkhitaryan, and Olesya Vasilkovskaya. "Therapy of coronavirus infection." International Journal of High Dilution Research - ISSN 1982-6206 20, no. 1 (March 28, 2021): 03–04. http://dx.doi.org/10.51910/ijhdr.v20i1.1078.
Full textAbstract:
Background: The computer apparatus for electro-acupuncture diagnostics and medicated testing "IMEDIS-EXPERT" made in Russia was used for the purposes of this work to detect SARS-CoV-2 (COVID-19) or to prove its absence, and to select homoeopathic preparations, nosodes, and their relevant doses. The methods of the system-nosological approach (SNA) were used for the therapy of patients, which included recording and appliance of relevant control signals (C.S.) of homoeopathic preparations, both native and informational (electronic) copies. Aims: 1. Develop an algorithm to select preparations from the group of nosodes and homoeopathy to prevent the development of SARS-CoV-2 (COVID-19); 2. Evaluate the possibility of preventing treatment and therapy of coronavirus infection employing an "electronic vaccine" produced employing coronavirus C.S. Methodology: The electronic preventing "immunization" was made for patients as the preventing treatment of COVID-19, which was an adaptation to coronavirus C.S. conducted in accordance with a special algorithm. The three-block scheme of SNA therapy was used for the therapy of ill patients, which was composed of three preparations, which were used sequentially: 1. Control signal of coronavirus targeted on a patient's CMH; 2. Cerebral response (C.R.) with a patient's cumulative impact of: C.S. of coronavirus and the sum of target organs (blood-forming system, lymphatic systems, lungs, bronchus, gastrointestinal system) and test-indicators of immune regulation targeted on the second CMH marker amplification; 3. Drainages in the form of homeopathic preparations were used (after the impact of two previous preparations), which were: Arsenicum, Arsenicum iod, Carbo vegetabilis, Spongia, Drosera, Naya, Rhus Toxicodendron, and Ferrum met. The preparations were selected to compensate the third impact of CMH. Results: At present, 175 people have asked for help due to COVID-19, an electronic preventing vaccine ("immunization") made for 112 people on the SNA algorithm. According to the diagnostic testing results made for 63 ill patients and who asked for treatment: 47 people tested coronavirus infection, 16 people tested ARVI, and 12 people tested pneumonia caused by a virus. The coincidence of VRT tests (vegetative resonance tests) and PCR was found ranged from 68 to 75%. 4 people got ill by coronavirus among those who got preventing immunization (112 people) by "the electronic sensibilization method" (that was proved by VRT and PCR tests). The illness had the light form among 2 of them, and two people had moderate severity of illness without hospital admission. Conclusion: An algorithm is developed, which allows to select C.S. of therapeutic nosodes and homoeopathic preparations to prevent the development of SARS-CoV-2. The efficiency of applying the electronic immunization method according to the algorithms of SNA using coronavirus C.S. is 95%.
23
Quinnan, Gerald V., Xiao-Fang Yu, Mark G. Lewis, Peng Fei Zhang, Gerd Sutter, Peter Silvera, Ming Dong, et al. "Protection of Rhesus Monkeys against Infection with Minimally Pathogenic Simian-Human Immunodeficiency Virus: Correlations with Neutralizing Antibodies and Cytotoxic T Cells." Journal of Virology 79, no. 6 (March 15, 2005): 3358–69. http://dx.doi.org/10.1128/jvi.79.6.3358-3369.2005.
Full textAbstract:
ABSTRACT We studied the capacity of active immunization of rhesus monkeys with HIV-1 envelope protein (Env) to induce primary virus cross-reactive neutralizing antibodies to prevent infection following intravenous challenge with simian-human immunodeficiency virus (SHIV). Monkeys were immunized with the human immunodeficiency type 1 (HIV-1) strain R2 Env. Initially, the Env was expressed in vivo by an alphavirus replicon particle system, and then it was administered as soluble oligomeric gp140. Concurrently, groups of monkeys received expression vectors that encoded either simian immunodeficiency virus (SIV) gag/pol genes or no SIV genes in vivo to test the additional protective benefit of concurrent induction of virus-specific cell-mediated immune (CMI) responses. Groups of control monkeys received either the gag/pol regimen or sham immunizations. The antibodies induced by the Env immunization regimen neutralized diverse primary HIV-1 strains. Similarly, potent CMI responses were induced by the gag/pol regimen, as measured by gamma interferon enzyme-linked immunospot assays. Differences in the responses among groups of monkeys strongly suggested that there was interference between the Env and gag/pol immunization regimens. Complete protection of some of the monkeys against infection after intravenous challenge with the partially pathogenic SHIVDH12R (Clone 7) was associated independently with both neutralizing antibody and CMI responses. Protection was associated with SHIVDH12 (Clone 7) serum neutralizing antibody titers of ≥1:80 or with cellular immune responses corresponding to >2,000 spot forming cells per 106 peripheral blood mononuclear cells. Immunization was also associated with a reduction in the magnitude and duration of virus load. Induction of cross-reactive, primary HIV-1-neutralizing antibodies is feasible and, when potent, may result in complete protection against infection with a heterologous challenge virus strain.
24
Iyer, Smita S., Sailaja Gangadhara, Blandine Victor, Xiaoying Shen, Xuemin Chen, Rafiq Nabi, Sudhir P. Kasturi, et al. "Virus-Like Particles Displaying Trimeric Simian Immunodeficiency Virus (SIV) Envelope gp160 Enhance the Breadth of DNA/Modified Vaccinia Virus Ankara SIV Vaccine-Induced Antibody Responses in Rhesus Macaques." Journal of Virology 90, no. 19 (July 27, 2016): 8842–54. http://dx.doi.org/10.1128/jvi.01163-16.
Full textAbstract:
ABSTRACTThe encouraging results of the RV144 vaccine trial have spurred interest in poxvirus prime-protein boost human immunodeficiency virus (HIV) vaccine modalities as a strategy to induce protective immunity. Because vaccine-induced protective immunity is critically determined by HIV envelope (Env) conformation, significant efforts are directed toward generating soluble trimeric Env immunogens that assume native structures. Using the simian immunodeficiency virus (SIV)-macaque model, we tested the immunogenicity and efficacy of sequential immunizations with DNA (D), modified vaccinia virus Ankara (MVA) (M), and protein immunogens, all expressing virus-like particles (VLPs) displaying membrane-anchored trimeric Env. A single VLP protein boost displaying trimeric gp160 adjuvanted with nanoparticle-encapsulated Toll-like receptor 4/7/8 (TLR4/7/8) agonists, administered 44 weeks after the second MVA immunization, induced up to a 3-fold increase in Env-specific IgG binding titers in serum and mucosa. Importantly, the VLP protein boost increased binding antibody against scaffolded V1V2, antibody-dependent phagocytic activity against VLP-coated beads, and antibody breadth and neutralizing antibody titers against homologous and heterologous tier 1 SIVs. Following 5 weekly intrarectal SIVmac251 challenges, two of seven DNA/MVA and VLP (DM+VLP)-vaccinated animals were completely protected compared to productive infection in all seven DM-vaccinated animals. Vaccinated animals demonstrated stronger acute viral pulldown than controls, but a trend for higher acute viremia was observed in the DM+VLP group, likely due to a slower recall of Gag-specific CD8 T cells. Our findings support immunization with VLPs containing trimeric Env as a strategy to augment protective antibody but underscore the need for optimal engagement of CD8 T cells to achieve robust early viral control.IMPORTANCEThe development of an effective HIV vaccine remains a global necessity for preventing HIV infection and reducing the burden of AIDS. While this goal represents a formidable challenge, the modest efficacy of the RV144 trial indicates that multicomponent vaccination regimens that elicit both cellular and humoral immune responses can prevent HIV infection in humans. However, whether protein immunizations synergize with DNA prime-viral vector boosts to enhance cellular and humoral immune responses remains poorly understood. We addressed this question in a nonhuman primate model, and our findings show benefit for sequential protein immunization combined with a potent adjuvant in boosting antibody titers induced by a preceding DNA/MVA immunization. This promising strategy can be further developed to enhance neutralizing antibody responses and boost CD8 T cells to provide robust protection and viral control.
25
ALnashy, A. M. M. "Pathological changes inducing by Brucella mellitensis in mice immunized with Culture Filtrate Brucella mellitensis Antigens (SCFAgs) and chitosan." Al-Qadisiyah Journal of Veterinary Medicine Sciences 12, no. 2 (December 30, 2013): 70. http://dx.doi.org/10.29079/vol12iss2art260.
Full textAbstract:
In order to determine the influence of Culture Filtrate Brucella mellitensis Antigens (CFAgs) on B. mellitensis infection in chatosan immunostimulater mice, sixty for white mice, both sex,7-8 weeks age were divided randomly into for groups.1st group(n=16 ) was immunized with 0.4ml of CFSAgs B. mellitensis (concentration of protein( 4.2mg/ml) ,i/p two doses, 2 weeks intervals. 2nd group(n=16) was feed on diet supplement with chitosan ,(1mg/kg B.W) 4 weeks. group. 3ed group(n=1) was inoculated with (0.4ml) I/P with1X109 CFU/ML of viable virulent B. mellitensis and was served as control positive group. 4th group (n=16) was inoculated with 0.5ml sterile normal saline. Cellular and humoral immune response were recorded at 28-30 day post immunization, skin test and passive heam agglutination test respectively, then all animals of immunized and feed chatosan groups were challenge with B. mellitensis as control positive group. The results explained that dead for animals in cotral positive during 15 days post inoculation with virulent viable B. mellitensi with very heavy bacterial isolation, from animal of control positive group post infection The results revealed that immunization with CFSAgs elicited both humoral and cellular immune responses, the level values of both arms of immune response also result reveald that immunization with CFSAgs + chatosan elicited both humoral and cellular immune responses higher than other group , Severe pathological lesions were seen in examined organs of control positive group but these lesions are mild or few in animal immunization with CFSAgs + chatosan. The main lesions in examined organs of these animals are suppurative inflammation ,small grnulomma .. We conclusion that immunization with CFSAgs + chatosan can improve the immune responses in the animals that are suffering from Brucella mellitensis infection
26
Blackstock, Rebecca, and Juneann W. Murphy. "Age-Related Resistance of C57BL/6 Mice to Cryptococcus neoformans Is Dependent on Maturation of NKT Cells." Infection and Immunity 72, no. 9 (September 2004): 5175–80. http://dx.doi.org/10.1128/iai.72.9.5175-5180.2004.
Full textAbstract:
ABSTRACT Conflicting results have been reported regarding the ability of C57BL/6 mice to clear infections due to Cryptococcus neoformans. Examination of the various experimental protocols used suggested that C57BL/6 mice might develop the ability to resist infection as they mature. We analyzed the ability of C57BL/6 mice of different ages to respond to immunization with cryptococcal antigen or to clear a cryptococcal infection. Mice were immunized with a soluble cryptococcal culture filtrate antigen (CneF) emulsified in complete Freund's adjuvant (CneF-CFA). Delayed-type hypersensitivity (DTH) reactions elicited by the immunization were significantly stronger in 15-week-old C57BL/6 mice than in 7-week-old mice. Analysis of cryptococcal CFU 8 weeks following intratracheal infection of 7-week-old mice or 15-week-old mice revealed a relative inability of the younger animals to control the infection. Six-week-old immunized and infected mice cleared cryptococci from brain, spleen, and liver in a manner similar to that of immunized and infected 15-week-old mice. However, the older mice cleared cryptococci much more efficiently from the lungs. The possible role for NKT cells was determined by passive transfer of thymocytes from 10-week-old mice (containing mature NKT cells) or 2-week-old mice (containing immature NKT cells) to 6-week-old mice. The 10-week-old thymocytes significantly enhanced the ability of the mice to develop a DTH response after immunization with CneF-CFA, while animals treated with 2-week-old thymocytes did not improve their DTH response after immunization. The cells in the 10-week-old thymocyte population responsible for improvement of DTH responses were identified as being NK1.1 positive.
27
Dennehy, Penelope H. "Active Immunization in the United States: Developments over the Past Decade." Clinical Microbiology Reviews 14, no. 4 (October 1, 2001): 872–908. http://dx.doi.org/10.1128/cmr.14.4.872-908.2001.
Full textAbstract:
SUMMARY The Centers for Disease Control and Prevention has identified immunization as the most important public health advance of the 20th century. The purpose of this article is to review the changes that have taken place in active immunization in the United States over the past decade. Since 1990, new vaccines have become available to prevent five infectious diseases: varicella, rotavirus, hepatitis A, Lyme disease, and Japanese encephalitis virus infection. Improved vaccines have been developed to prevent Haemophilus influenzae type b, pneumococcus, pertussis, rabies, and typhoid infections. Immunization strategies for the prevention of hepatitis B, measles, meningococcal infections, and poliomyelitis have changed as a result of the changing epidemiology of these diseases. Combination vaccines are being developed to facilitate the delivery of multiple antigens, and improved vaccines are under development for cholera, influenza, and meningococcal disease. Major advances in molecular biology have enabled scientists to devise new approaches to the development of vaccines against diseases ranging from respiratory viral to enteric bacterial infections that continue to plague the world's population.
28
Cunha, Cristina W., Travis C. McGuire, Lowell S. Kappmeyer, Stephen A. Hines, A. Marianela Lopez, Odir A. Dellagostin, and Donald P. Knowles. "Development of Specific Immunoglobulin Ga (IgGa) and IgGb Antibodies Correlates with Control of Parasitemia in Babesia equi Infection." Clinical and Vaccine Immunology 13, no. 2 (February 2006): 297–300. http://dx.doi.org/10.1128/cvi.13.2.297-300.2006.
Full textAbstract:
ABSTRACT In this study, the kinetics of specific immunoglobulin G (IgG) isotypes were characterized in Babesia equi (Theileria equi)-infected horses. IgGa and IgGb developed during acute infection, whereas IgG(T) was detected only after resolution of acute parasitemia. The same IgG isotype profile induced during acute infection was obtained by equi merozoite antigen 1/saponin immunization.
29
Gómez, Marisa I., Daniel O. Sordelli, Fernanda R. Buzzola, and Verónica E. García. "Induction of Cell-Mediated Immunity to Staphylococcus aureus in the Mouse Mammary Gland by Local Immunization with a Live Attenuated Mutant." Infection and Immunity 70, no. 8 (August 2002): 4254–60. http://dx.doi.org/10.1128/iai.70.8.4254-4260.2002.
Full textAbstract:
ABSTRACT The efficacy of intramammary (Ima) immunization with a live attenuated (la) Staphylococcus aureus mutant to protect the mouse mammary gland from infection has previously been established. The present study was aimed at evaluating whether Ima immunization with la-S. aureus can induce cell-mediated immune responses to the pathogen within the mammary gland. Mice were immunized by Ima route with la-S. aureus, and regional lymph node mononuclear cells were obtained thereafter. A higher expression of the interleukin-2 receptor was found on B and T cells from immunized mice when they were compared with control mice. Immunization with la-S. aureus induced strong proliferative responses to S. aureus. Moreover, significantly increased levels of gamma interferon (IFN-γ) were produced by CD4+ T cells when lymphocytes from immunized mice, but not from control mice, were cultured in the presence of staphylococcal antigens. Moreover, a significant increase in the percentage of IFN-γ-producing CD4+ and CD8+ T cells was observed after S. aureus Ima challenge in immunized mice compared to challenged control mice. Our results demonstrated that Ima immunization with la-S. aureus induced primed lymphocyte populations capable of responding against staphylococcal antigens during in vitro stimulation, as well as during in vivo infection by S. aureus. CD4+ and CD8+ T cells appear to be the main lymphocyte subpopulations involved in this response. It is suggested that IFN-γ production induced by Ima immunization may play a pivotal role in the eradication of intracellular staphylococci.
30
COUDEVILLE, L., A. VAN RIE, and P. ANDRE. "Adult pertussis vaccination strategies and their impact on pertussis in the United States: evaluation of routine and targeted (cocoon) strategies." Epidemiology and Infection 136, no. 5 (July 5, 2007): 604–20. http://dx.doi.org/10.1017/s0950268807009041.
Full textAbstract:
SUMMARYA compartmental, age-structured mathematical model was developed and recent US pertussis epidemiology data were used to evaluate the impact on pertussis infection rates of routine and targeted adult immunization strategies. Model simulations predict that the implementation of adolescent immunization only could reverse the current rise in pertussis infection rates but may lead to a resurgence of pertussis in subsequent decades. In contrast, inclusion of a routine adult strategy is likely to lead to sustained control of pertussis. Routine adult vaccination could control the disease even with relatively low coverage rates of 40% for routine vaccination of all adults every 10 years, or 65% for a targeted vaccination of close contacts of newborns completed by one booster dose for all adults. The model also predicts that the optimal age for this booster dose is 40 years. These results support the 2006 American Academy of Immunization Practices' recommendations for adolescent and adult vaccination against pertussis.
31
Shah, P., and E. Swiatlo. "Immunization with Polyamine Transport Protein PotD Protects Mice against Systemic Infection with Streptococcus pneumoniae." Infection and Immunity 74, no. 10 (October 2006): 5888–92. http://dx.doi.org/10.1128/iai.00553-06.
Full textAbstract:
ABSTRACT The human pathogen Streptococcus pneumoniae contains genes for a putative polyamine ABC transporter which are organized in an operon and designated potABCD. Polyamine transport protein D (PotD) is an extracellular protein which binds polyamines and possibly other structurally related molecules. PotD has been shown to contribute to virulence in both a murine sepsis model and a pneumonia model with capsular type 3 pneumococci. The protective efficacy of recombinant PotD was evaluated by active immunization and intravenous challenge with capsular type 3 pneumococci in CBA/N mice. Immunized mice had 91.7% survival following lethal pneumococcal challenge, compared with 100% mortality in the control group. Immunized animals had high-titer anti-PotD antibodies following three immunizations with alum. Protection in a sepsis model was also seen after passive administration of rabbit antiserum raised against PotD (P < 0.004). These results suggest that antibodies to PotD confer protection against invasive pneumococcal disease and that this protein should be studied further as a potential vaccine candidate for protection against invasive pneumococcal infections.
32
Mohamed, Azza H. "Immunization efficacy of ozone-exposed cercariae against subsequent Schistosoma mansoni challenge infection." Animal Biology 61, no. 3 (2011): 289–301. http://dx.doi.org/10.1163/157075511x584236.
Full textAbstract:
AbstractCD1 mice were immunized subcutaneously with 20 ozone-exposed (70μg/ml, 1 minute exposure) Schistosoma mansoni cercariae weekly/three weeks. The efficacy of immunization was assessed 10 weeks post challenge infection by the determination of the worm burden, ova count, oogram, granuloma diameter, IgG reactions against soluble egg antigen (SEA) and tegument structural changes of recovered worms that are immunized. A reduced worm length and a reduction in worm burden were observed in the immunized group as compared to the infected not immunized group. Moreover, no ova were found in liver and intestine from the immunized mice as compared with infected control mice. Also, immunization with ozonated cercariae showed a decrement in the mean relative weight of liver and spleen. Total leukocyte count was increased in the immunized animal as compared to the infected control. The level of total IgG antibody against SEA decreased in immunized mice as compared with the infected control mice. Scanning electron microscope (SEM) images of worms recovered 10 weeks post challenge from the immunized group revealed extensive tegumental destruction. This study underlines the significant role of ozone attenuated cercariae vaccine against S. mansoni infection, which generated specific immunity with a significant level of protection.
33
Han, Sushan, Junzo Norimine, Kelly A. Brayton, Guy H. Palmer, Glen A. Scoles, and Wendy C. Brown. "Anaplasma marginale Infection with Persistent High-Load Bacteremia Induces a Dysfunctional Memory CD4+ T Lymphocyte Response but Sustained High IgG Titers." Clinical and Vaccine Immunology 17, no. 12 (October 13, 2010): 1881–90. http://dx.doi.org/10.1128/cvi.00257-10.
Full textAbstract:
ABSTRACT Control of blood-borne infections is dependent on antigen-specific effector and memory T cells and high-affinity IgG responses. In chronic infections characterized by a high antigen load, it has been shown that antigen-specific T and B cells are vulnerable to downregulation and apoptosis. Anaplasma marginale is a persistent infection of cattle characterized by acute and chronic high-load bacteremia. We previously showed that CD4+ T cells primed by immunization with an A. marginale outer membrane protein were rapidly deleted following infection. Furthermore, peripheral blood T cell responses to bacteria were not observed after acute infection was controlled, suggesting dysfunctional T cell priming to other A. marginale antigens. The current study more closely investigated the kinetics of A. marginale-specific CD4+ T cell responses primed during infection. Frequent sampling of peripheral blood and spleens revealed that antigen-specific CD4+ T cell responses were first detected at 5 to 7 weeks, but the responses were sporadic and transient thereafter. A similar pattern was observed in animals sampled weekly for nearly 1 year. Paradoxically, by 2 weeks of infection, cattle had developed high titers of A. marginale-specific IgG, which remained high throughout persistent infection. This dysfunctional CD4+ T cell response to infection is consistent with continual downregulation or deletion of newly primed effector T cells, similar to what was observed for immunization-induced T cells following A. marginale infection. The failure to establish a strong memory T cell response during A. marginale infection likely contributes to bacterial persistence.
34
Nilsson, Charlotta, Gerd Sutter, Lilian Walther-Jallow, Peter ten Haaft, Lennart Åkerblom, Jonathan Heeney, Volker Erfle, Per Böttiger, Gunnel Biberfeld, and Rigmor Thorstensson. "Immunization with recombinant modified vaccinia virus Ankara can modify mucosal simian immunodeficiency virus infection and delay disease progression in macaques." Journal of General Virology 83, no. 4 (April 1, 2002): 807–18. http://dx.doi.org/10.1099/0022-1317-83-4-807.
Full textAbstract:
In the present study, the immunogenicity and protective efficacy of a recombinant vaccinia virus-based simian immunodeficiency virus (SIV) vaccine, given alone or in combination with a protein boost, were investigated. Cynomolgus macaques were immunized intramuscularly with modified vaccinia virus Ankara (MVA) expressing the SIVsm env and gag–pol genes (MVA–SIVsm) at 0 and 3 months (n=4), at 0, 3 and 8 months (n=4) or at 0 and 3 months followed by purified native SIVsm gp148 and recombinant SIVmac p27 in immunostimulatory complexes at 8 months (n=4). One month after the last immunization, the vaccinees, together with four naive control monkeys and four monkeys immunized with wild-type MVA, were challenged intrarectally with 10 MID50 SIVsm. At the time of challenge, antibody titres to SIV Env and lymphocyte proliferation responses to whole viral antigen were highest in vaccinees receiving MVA–SIVsm in combination with protein immunizations. Following rectal challenge, one of these vaccinees was completely protected. A prolonged survival time was observed in two of four monkeys in each of the groups immunized with MVA–SIVsm, in two monkeys given MVA–SIVsm followed by protein and in three of four monkeys given wild-type MVA, compared with naive controls. In conclusion, one monkey given the combined vaccine was protected completely against SIVsm infection. Furthermore, immunization with MVA–SIVsm, as well as wild-type MVA alone, seemed to delay disease progression after mucosal SIV infection in a proportion of the monkeys.
35
Shen, Ling, James Frencher, Dan Huang, Wandang Wang, Enzhuo Yang, Crystal Y. Chen, Zhuoran Zhang, et al. "Immunization of Vγ2Vδ2 T cells programs sustained effector memory responses that control tuberculosis in nonhuman primates." Proceedings of the National Academy of Sciences 116, no. 13 (March 8, 2019): 6371–78. http://dx.doi.org/10.1073/pnas.1811380116.
Full textAbstract:
Tuberculosis (TB) remains a leading killer among infectious diseases, and a better TB vaccine is urgently needed. The critical components and mechanisms of vaccine-induced protection againstMycobacterium tuberculosis(Mtb) remain incompletely defined. Our previous studies demonstrate that Vγ2Vδ2 T cells specific for (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate (HMBPP) phosphoantigen are unique in primates as multifunctional effectors of immune protection against TB infection. Here, we selectively immunized Vγ2Vδ2 T cells and assessed the effect on infection in a rhesus TB model. A single respiratory vaccination of macaques with an HMBPP-producing attenuatedListeria monocytogenes(LmΔactA prfA*) caused prolonged expansion of HMBPP-specific Vγ2Vδ2 T cells in circulating and pulmonary compartments. This did not occur in animals similarly immunized with an LmΔgcpEstrain, which did not produce HMBPP. LmΔactA prfA* vaccination elicited increases in Th1-like Vγ2Vδ2 T cells in the airway, and induced containment of TB infection after pulmonary challenge. The selective immunization of Vγ2Vδ2 T cells reduced lung pathology and mycobacterial dissemination to extrapulmonary organs. Vaccine effects coincided with the fast-acting memory-like response of Th1-like Vγ2Vδ2 T cells and tissue-resident Vγ2Vδ2 effector T cells that produced both IFN-γ and perforin and inhibited intracellular Mtb growth. Furthermore, selective immunization of Vγ2Vδ2 T cells enabled CD4+and CD8+T cells to mount earlier pulmonary Th1 responses to TB challenge. Our findings show that selective immunization of Vγ2Vδ2 T cells can elicit fast-acting and durable memory-like responses that amplify responses of other T cell subsets, and provide an approach to creating more effective TB vaccines.
36
Mayhall, C. Glen, and John M. Boyce. "Treatment and Control of Colonization in the Prevention of Nosocomial Infections." Infection Control & Hospital Epidemiology 17, no. 4 (April 1996): 256–61. http://dx.doi.org/10.1017/s0195941700003866.
Full textAbstract:
AbstractPatients frequently develop nosocomial infections that are caused by normal flora colonizing the patient at the time of admission, or by exogenous pathogens that are acquired and subsequently colonize the patient after admission to the hospital. To prevent nosocomial infections, a variety of strategies have been used either to prevent colonization from occurring, to eradicate colonizing organisms, or to prevent the progression from colonization to infection. These strategies include implementation of infection control measures designed to prevent acquisition of exogenous pathogens, eradication of exogenous pathogens from patients or personnel who have become colonized, suppression of normal flora, prevention of colonizing flora from entering sterile body sites during invasive procedures, microbial interference therapy, immunization of high-risk patients, and modification of antibiotic utilization practices. Because strategies that require widespread use of antimicrobial agents to suppress or eradicate colonizing organisms tend to promote emergence of multidrug-resistant pathogens, greater emphasis should be given to those strategies that prevent colonization from occurring or employ techniques other than administration of prophylactic antibiotics to eradicate colonization. Restricting inappropriate use of antibiotics should reduce the frequency with which patients become colonized and infected with multidrug-resistant organisms.
37
Brandsma, Janet L., Mark Shlyankevich, Lixin Zhang, Martin D. Slade, Edward C. Goodwin, Woei Peh, and Albert B. Deisseroth. "Vaccination of Rabbits with an Adenovirus Vector Expressing the Papillomavirus E2 Protein Leads to Clearance of Papillomas and Infection." Journal of Virology 78, no. 1 (January 1, 2004): 116–23. http://dx.doi.org/10.1128/jvi.78.1.116-123.2004.
Full textAbstract:
ABSTRACT Cervical cancer arises from lesions caused by infection with high-risk types of human papillomavirus (HPV). Therefore, vaccination against HPV could prevent carcinogenesis by preventing HPV infection or inducing lesion regression. HPV E2 protein is an attractive candidate for vaccine development because it is required for papilloma formation, is involved in all stages of the virus life cycle, and is expressed in all premalignant lesions as well as some cancers. This study reports vaccination against E2 protein using a rabbit model of papillomavirus infection. A recombinant adenovirus (Ad) vector expressing the E2 protein of cottontail rabbit papillomavirus (CRPV) was tested for therapeutic efficacy in CRPV-infected rabbits. Primary immunization with the Ad-E2 vaccine, compared to immunization with a control Ad vector, reduced the number of papilloma-forming sites from 17 of 45 to 4 of 45. After booster immunization, vaccinated rabbits formed no new papillomas versus an additional 23 papillomas in rabbits that received the control vector. Papillomas in the Ad-E2 vaccinees were significantly smaller than those in the control rabbits, and all four papillomas in the Ad-E2 vaccinated rabbits regressed. No CRPV DNA was detected either in the regression sites or in sites that did not form papillomas, indicating that the vaccination led to clearance of CRPV from all infected sites.
38
THORBURN, K. M., R. BOHORQUES, P. STEPAK, L. L. SMITH, C. JOBB, and J. PALMER SMITH. "Immunization strategies to control a community-wide hepatitis A epidemic." Epidemiology and Infection 127, no. 3 (December 2001): 461–67. http://dx.doi.org/10.1017/s0950268801006008.
Full textAbstract:
One fifth of 527 cases of hepatitis A occurred in self-identified injection drug users during a community-wide epidemic in Spokane County (Washington) in 1997–8. We hypothesized that an immunization campaign targeted at illicit drug users could control the epidemic. Starting in May 1998, hepatitis A vaccine was provided to individuals in jails and other sites frequented by illicit drug users. Volunteers at vaccination sites were surveyed about risk. Serial convenience samples of jail inmates who denied previous vaccination were anonymously tested for hepatitis A virus (HAV) immunoglobulin G (IgG). From May to December 1998, 2765 high-risk individuals were vaccinated against hepatitis A. The proportion of HAV IgG seropositive inmates increased from 30% to more than 50%. Our findings suggest that vaccination along with naturally occurring infection increased the rate of hepatitis A immunity among illicit drug users during the final months of the epidemic. This supports the hypothesis that targeted immunization of high risk groups may shorten the natural history of a community-wide epidemic.
39
Fassnacht, Ulrike, Andreas Ackermann, Peter Staeheli, and Jürgen Hausmann. "Immunization with dendritic cells can break immunological ignorance toward a persisting virus in the central nervous system and induce partial protection against intracerebral viral challenge." Journal of General Virology 85, no. 8 (August 1, 2004): 2379–87. http://dx.doi.org/10.1099/vir.0.80115-0.
Full textAbstract:
Dendritic cells (DCs) have been used successfully to induce CD8 T cells that control virus infections and growth of tumours. The efficacy of DC-mediated immunization for the control of neurotropic Borna disease virus (BDV) in mice was evaluated. Certain strains of mice only rarely develop spontaneous neurological disease, despite massive BDV replication in the brain. Resistance to disease is due to immunological ignorance toward BDV antigen in the central nervous system. Ignorance in mice can be broken by immunization with DCs coated with TELEISSI, a peptide derived from the N protein of BDV, which represents the immunodominant cytotoxic T lymphocyte epitope in H-2k mice. Immunization with TELEISSI-coated DCs further induced solid protective immunity against intravenous challenge with a recombinant vaccinia virus expressing BDV-N. Interestingly, however, this immunization scheme induced only moderate protection against intracerebral challenge with BDV, suggesting that immune memory raised against a shared antigen may be sufficient to control a peripherally replicating virus, but not a highly neurotropic virus that is able to avoid activation of T cells. This difference might be due to the lack of BDV-specific CD4 T cells and/or inefficient reactivation of DC-primed, BDV-specific CD8 T cells by the locally restricted BDV infection. Thus, a successful vaccine against persistent viruses with strong neurotropism should probably induce antiviral CD8 (as well as CD4) T-cell responses and should favour the accumulation of virus-specific memory T cells in cervical lymph nodes.
40
Hel, Zdenek, David Venzon, Monita Poudyal, Wen-Po Tsai, Laura Giuliani, Ruth Woodward, Claire Chougnet, et al. "Viremia control following antiretroviral treatment and therapeutic immunization during primary SIV251 infection of macaques." Nature Medicine 6, no. 10 (October 2000): 1140–46. http://dx.doi.org/10.1038/80481.
Full text
41
Shi, Y. E., C. F. Jiang, J. J. Han, Y. L. Li, and A. Ruppel. "Immunization of pigs against infection with Schistosoma japonicum using ultraviolet-attenuated cercariae." Parasitology 106, no. 5 (June 1993): 459–62. http://dx.doi.org/10.1017/s0031182000076745.
Full textAbstract:
SUMMARYSince pigs are important in the zoonotic transmission of schistosomiasis japonica in China, a veterinary vaccine might contribute to the control of the disease in humans. Pigs were immunized with three doses each of 10000 cercariae of Schistosoma japonicum attenuated with ultraviolet light (400 μWatt·min/cm2). The experiment was performed with portable irradiation equipment in a rural area of the Hubei Province (P.R. China). A challenge infection of 1000 untreated cercariae was given 2·5 or 6 months after the last immunization, and age-matched naive pigs were challenged as a control. Immunized pigs developed about 90% resistance against the challenge. The liver egg load of these animals was reduced by over 90%. Less than 0·01 % of the immunizing cercariae developed to adult parasites and the vaccination had no apparent adverse influence on the pigs' health.
42
Alvarado-Ramy, Francisco, Miriam J. Alter, William Bower, David K. Henderson, Annette H. Sohn, Ronda L. Sinkowitz-Cochran, and William R. Jarvis. "Management of Occupational Exposures to Hepatitis C Virus Current Practice and Controversies." Infection Control & Hospital Epidemiology 22, no. 1 (January 2001): 53–55. http://dx.doi.org/10.1086/501824.
Full textAbstract:
AbstractUnlike hepatitis B virus and human immunodeficiency virus, there currently are no immunization or chemoprophylactic interventions available to prevent infection after an occupational exposure to hepatitis C virus (HCV). A “Reality Check” session was held at the 4th Decennial International Conference on Nosocomial and Healthcare-Associated Infections to gather information on current practices related to management of occupational exposures to HCV, generate discussion on controversial issues, and identify areas for future research. Infection control professionals in attendance were knowledgeable in most issues addressed regarding the management of occupational exposures to HCV. Areas of controversy included the use of antiviral therapy early in the course of HCV infection and the appropriate administrative management of an HCV-infected healthcare worker.
43
Li, Yuanyi, Marcelo Gottschalk, Miriam Esgleas, Sonia Lacouture, J. Daniel Dubreuil, Philip Willson, and Josee Harel. "Immunization with Recombinant Sao Protein Confers Protection against Streptococcus suis Infection." Clinical and Vaccine Immunology 14, no. 8 (June 13, 2007): 937–43. http://dx.doi.org/10.1128/cvi.00046-07.
Full textAbstract:
ABSTRACT Sao is a Streptococcus suis surface protein recently identified as a potential vaccine candidate. In this study, recombinant Sao in combination with Quil A provided cross-protection against S. suis serotype 2 disease in mouse and pig vaccination protocols. Subcutaneous immunization of mice elicited strong immunoglobulin G (IgG) antibody responses. All four IgG subclasses were induced, with the IgG2a titer being the highest, followed by those of IgG1, IgG2b, and IgG3. Challenge of the mice with S. suis strain 31533 resulted in a mortality rate of 80% for the control group, which received Quil A only. In contrast, all of the mice immunized with Sao survived. In a pig vaccination protocol, intramuscular immunization with Sao also elicited significant humoral antibody responses, and both the IgG1 and IgG2 subclasses were induced, with a predominance of IgG2 production. In vitro assay showed that Sao-induced antibodies significantly promoted the ability of porcine neutrophils in opsonophagocytic killing of S. suis. An aerosol challenge of the pigs with S. suis strain 166 resulted in clinical signs characteristic of S. suis infection in diseased pigs. The vaccine group showed significantly better survival, lower clinical scores, and less S. suis recovery from postmortem tissue samples than did the control group. Furthermore, this study also revealed that although challenge S. suis strains express Sao size variants, recombinant Sao conferred cross-protection. These data demonstrate that recombinant Sao formulated with Quil A triggers strong opsonizing antibody responses which confer efficient immunity against challenge infection with heterologous S. suis type 2.
44
Hu, Dong-Liang, Jing-Chun Cui, Katsuhiko Omoe, Hiroshi Sashinami, Yuichi Yokomizo, Kunihiro Shinagawa, and Akio Nakane. "A Mutant of Staphylococcal Enterotoxin C Devoid of Bacterial Superantigenic Activity Elicits a Th2 Immune Response for Protection against Staphylococcus aureus Infection." Infection and Immunity 73, no. 1 (January 2005): 174–80. http://dx.doi.org/10.1128/iai.73.1.174-180.2005.
Full textAbstract:
ABSTRACT Staphylococcal enterotoxin C (SEC), a bacterial superantigenic exotoxin, is commonly produced by invasive Staphylococcus aureus isolates, especially methicillin-resistant strains and isolates from animal diseases. We constructed and expressed a nontoxic mutant SEC (mSEC) and investigated whether immunization with mSEC, which is devoid of superantigenic activity, can protect against S. aureus infection. Mice were immunized with mSEC and challenged with viable S. aureus. The bacterial counts in the organs of mSEC-immunized mice were significantly lower and the survival rate was higher than the corresponding values for the control group. Immunization with mSEC strongly induced the production of T-helper 2 type antibodies, immunoglobulin G1, and immunoglobulin G2b. The production of interleukin-10 (IL-10) and IL-4 was significantly greater in immunized mice challenged with S. aureus than in the control mice, whereas the production of gamma interferon (IFN-γ) was significantly decreased in the immunized mice. The cytokine response in a spleen cell culture that was stimulated with heat-killed S. aureus or SEC showed that immunization with mSEC inhibited IFN-γ production and up-regulated IL-10 production in vitro. Furthermore, IFN-γ and tumor necrosis factor alpha production in vitro was significantly inhibited by sera from mSEC-immunized mice but not by sera from control mice. These results suggest that immunization with mSEC devoid of superantigenic properties provides protection against S. aureus infection and that the protection might be mediated by SEC-specific neutralizing antibodies.
45
Rodrigues, Marcio L., Li Shi, Eliana Barreto-Bergter, Leonardo Nimrichter, Sandra E. Farias, Elaine G. Rodrigues, Luiz R. Travassos, and Joshua D. Nosanchuk. "Monoclonal Antibody to Fungal Glucosylceramide Protects Mice against Lethal Cryptococcus neoformans Infection." Clinical and Vaccine Immunology 14, no. 10 (August 22, 2007): 1372–76. http://dx.doi.org/10.1128/cvi.00202-07.
Full textAbstract:
ABSTRACT Glucosylceramides (GlcCer) are involved in the regulation of Cryptococcus neoformans virulence. In the present study, we demonstrate that passive immunization with a monoclonal antibody to GlcCer significantly reduces host inflammation and prolongs the survival of mice lethally infected with C. neoformans, revealing a potential therapeutic strategy to control cryptococcosis.
46
Makhmudova, N. R., I. A. Leneva, N. V. Larionova, A. V. Poddubikov, I. N. Falynskova, N. P. Kartashova, and O. A. Svitich. "The safety of attenuated and recombinant nasal influenza vaccines in terms of the development of secondary bacterial superinfection." Journal of microbiology epidemiology immunobiology, no. 6 (December 16, 2019): 30–39. http://dx.doi.org/10.36233/0372-9311-2019-6-30-39.
Full textAbstract:
Introduction. Influenza is a severe viral disease. The most common post-influenza complication is pneumonia. Earlier, we developed an experimental mouse model of viralbacterial pneumonia induced by successive infection with influenza virus and St. aureus, in which lethal synergy between pathogens observed in epidemiological observations was detected.Aim. To study the effect of the administration of intranasal vaccines, followed by infection with St. pneumoniae on the development and completion of the disease.Materials and methods. The animals were immunized intranasal with a strain of attenuated cold-adapted live influenza vaccine A/17/California/2009/38 (H1N1)pdm09 (LAIV) and a recombinant vaccine based on virus-like particles HA(Puerto Rico/8/34)- Gag (VLPs). Control groups of animals were infected with virulent strains of influenza virus A/ California/04/2009 (H1N1)pdm09 or A/Puerto Rico /8/34 (H1N1). On the fifth day after intranasal immunization with the vaccine preparations and infection with pathogenic strains, animals were subjected to bacterial infection with a strain of St. pneumoniae. The presence of synergism of vaccine or viral agent with bacterial infection was assessed by survival and weight loss of animals, virus titer and density of bacteria in nasopharyngeal washes and lungs.Results. It was shown that immunization with vaccine preparations did not lead to increased sensitivity of mice to bacterial infection. Elimination of bacteria from the lungs and nasopharynx in groups immunized with vaccine preparations corresponded to the dynamics in the group of animals immunized by PBS.Discussion. The results obtained indicate the safety of intranasal immunization with LAIV A/17/California/2009/38 (H1N1)pdm09 and virus-like particles HA (Puerto Rico/8/34)- Gag (VLPs) in terms of enhancing secondary bacterial superinfection caused by St. pneumoniae.Conclusion. The studied vaccines successfully blocked infections in the lower respiratory tract.
47
Namazova-Baranova, Leyla S., Marina V. Fedoseenko, and Alexander A. Baranov. "New Horizons of National Immunization Calendar." Current Pediatrics 18, no. 1 (April 11, 2019): 13–30. http://dx.doi.org/10.15690/vsp.v18i1.1988.
Full textAbstract:
Containment, prevention and elimination of infectious disease is the state duty for citizens. Development of the National Immunization Calendar as well as challenges in preventive vaccination system both are significant investment into the future. Advantages of vaccination are not limited only by infection diseases control. Experts of World Health Organization recognize positive influence of immunization on economic. Vaccines give unprecedented opportunities on alleviation of human sufferings but it can be possible only due to perfect work of immunization calendar. It is necessary to estimate our National Immunization Calendar alongside with suggested by World Health Organization and professional associations plans. It is essential to estimate experience and facilities of modern vaccinology. This entailed the optimal preventive vaccination schedule, which can be implemented in the structure of existing national calendar.
48
Ludewig, Burkhard, Stephan Ehl, Urs Karrer, Bernhard Odermatt, Hans Hengartner, and Rolf M. Zinkernagel. "Dendritic Cells Efficiently Induce Protective Antiviral Immunity." Journal of Virology 72, no. 5 (May 1, 1998): 3812–18. http://dx.doi.org/10.1128/jvi.72.5.3812-3818.1998.
Full textAbstract:
ABSTRACT Cytotoxic T lymphocytes (CTL) are essential for effective immunity to various viral infections. Because of the high speed of viral replication, control of viral infections imposes demanding functional and qualitative requirements on protective T-cell responses. Dendritic cells (DC) have been shown to efficiently acquire, transport, and present antigens to naive CTL in vitro and in vivo. In this study, we assessed the potential of DC, either pulsed with the lymphocytic choriomeningitis virus (LCMV)-specific peptide GP33-41 or constitutively expressing the respective epitope, to induce LCMV-specific antiviral immunity in vivo. Comparing different application routes, we found that only 100 to 1,000 DC had to reach the spleen to achieve protective levels of CTL activation. The DC-induced antiviral immune response developed rapidly and was long lasting. Already at day 2 after a single intravenous immunization with high doses of DC (1 × 105 to 5 × 105), mice were fully protected against LCMV challenge infection, and direct ex vivo cytotoxicity was detectable at day 4 after DC immunization. At day 60, mice were still protected against LCMV challenge infection. Importantly, priming with DC also conferred protection against infections in which the homing of CTL into peripheral organs is essential: DC-immunized mice rapidly cleared an infection with recombinant vaccinia virus-LCMV from the ovaries and eliminated LCMV from the brain, thereby avoiding lethal choriomeningitis. A comparison of DC constitutively expressing the GP33-41 epitope with exogenously peptide-pulsed DC showed that in vivo CTL priming with peptide-loaded DC is not limited by turnover of peptide-major histocompatibility complex class I complexes. We conclude that the priming of antiviral CTL responses with DC is highly efficient, rapid, and long lasting. Therefore, the use of DC should be considered as an efficient means of immunization for antiviral vaccination strategies.
49
KEDZIERSKI, L., J. M. CURTIS, and K. KEDZIERSKA. "Early CD44hiCD4+ and CD44hiCD8+ T cell numbers and the absence of mannose-rich glycoconjugates determine the protective outcome of anti-leishmanial immunity." Parasitology 136, no. 8 (June 2, 2009): 833–40. http://dx.doi.org/10.1017/s0031182009006301.
Full textAbstract:
SUMMARYVaccination remains the best hope for control of all forms of leishmaniasis, and the development of a safe and effective vaccine is a critical global public-health priority. Our previous work showed that immunization with non-persistent phosphomannomutase-deficient (ΔPMM) Leishmania major parasites confers significant protection in susceptible BALB/c mice due to increased T-cell numbers and suppression of IL-10 and IL-13 early during infection. Here, we complemented the ΔPMM L. major parasites with human PMM2 to determine whether we could further improve the protection. Complemented ΔPMM parasites have restored glycoconjugate biosynthesis, while retaining avirulence of the parental knockout strain. Immunization with hPMM2 add-back parasites showed similar Th1/Th2 cytokine profiles to that observed in ΔPMM-vaccinated mice. However, the numbers of the activated CD4+CD44hi and CD8+CD44hi T cells recruited to the draining lymph nodes early after Leishmania infection were reduced, leading to decreased protection following hPMM2-immunization. Thus, the magnitude of T-cell responses early in the infection and the absence of mannose-rich glycoconjugates determine the protective outcome of anti-leishmanial immunity.
50
Khan, A. I., Y. Horii, N. Ishikawa, and Y. Nawa. "Effects of adoptive transfer of immune spleen cells on worm growth and microfilaraemia inBrugia pahangiinfection in Mongolian gerbils." Journal of Helminthology 69, no. 4 (December 1995): 331–35. http://dx.doi.org/10.1017/s0022149x00014917.
Full textAbstract:
AbstractProtective immunity againstBrugia pahangiwas examined after adoptive transfer of immune spleen cells. Spleen cells obtained from gerbils at 8 weeks post-infection (p.i.) with 100 infective larvae (L3) ofB. pahangiwere transferred into naive recipients, and then 24 h later, they were infected with 100 L3ofB. pahangi. The recipients given normal spleen cells and infected by the same manner served as controls. Microfilarial counts in the circulation were monitored at designated times after infection and worm burden and the size of individual female worm were determined at 16 weeks p.i. to evaluate the effects of adoptive immunization. In addition, eosinophil responses and serum antibody titres were examined during the course of infection. In the control group, microfilariae first appeared in circulation at 9 weeks p.i. and continuously increased in number throughout the course examined. In contrast, microfilaraemia was almost completely suppressed in the group given immune spleen cells. Although worm burden was comparable between the two groups, the average size of female adult worms recovered from the adoptively immunized group was significantlysmaller than that from the control group. Eosinophil response was hastened and enhanced by adoptive transfer of immune spleen cells in the early stage of infection. Parasite- specific antibody response was also hastened by adoptive immunization. These results suggest that immune spleen cells could confer protective immunity mainly directed against adultB. pahangi.